MedPath

Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma

Phase 2
Completed
Conditions
Gastrointestinal Stromal Tumor
Sarcoma
Registration Number
NCT00041249
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of brostallicin in treating patients who have locally advanced or metastatic soft tissue sarcoma that has not responded to one previous chemotherapy regimen.

Detailed Description

OBJECTIVES:

* Determine the antitumor activity of brostallicin, in terms of objective response, in patients with locally advanced or metastatic soft tissue sarcoma who have failed one prior chemotherapy treatment.

* Determine the time to progression and duration of response in patients treated with this drug.

* Determine the safety and toxic effects of this drug in these patients.

* Correlate clinical outcome with whole blood glutathione level in patients treated with this drug.

OUTLINE: This is a multicenter study. Patients are stratified according to tumor (tumors other than gastrointestinal stromal tumor (GIST) vs GIST).

Patients receive brostallicin IV over 10 minutes on day 1. Treatment repeats every 21 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed every 2 months for 1 year and then every 4 months for 1 year.

PROJECTED ACCRUAL: A total of 58-72 patients (40 for stratum I and 18-32 for stratum II) will be accrued for this study.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
64
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (16)

Klinikum Grosshadern der Ludwig-Maximilians Universitaet Muenchen

🇩🇪

Munich, Germany

Institut Gustave Roussy

🇫🇷

Villejuif, France

Universitaets-Krankenhaus Eppendorf

🇩🇪

Hamburg, Germany

Centre Leon Berard

🇫🇷

Lyon, France

Daniel Den Hoed Cancer Center at Erasmus University Medical Center

🇳🇱

Rotterdam, Netherlands

Robert Roessle Klinik

🇩🇪

Berlin, Germany

Medizinische Hochschule Hannover

🇩🇪

Hannover, Germany

U.Z. Gasthuisberg

🇧🇪

Leuven, Belgium

Royal Marsden NHS Trust - London

🇬🇧

London, England, United Kingdom

Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital

🇳🇱

Amsterdam, Netherlands

Universitair Ziekenhuis Antwerpen

🇧🇪

Edegem, Belgium

Leiden University Medical Center

🇳🇱

Leiden, Netherlands

Northern Centre for Cancer Treatment at Newcastle General Hospital

🇬🇧

Newcastle Upon Tyne, England, United Kingdom

St. James's University Hospital

🇬🇧

Leeds, England, United Kingdom

Academisch Ziekenhuis Groningen

🇳🇱

Groningen, Netherlands

CHU de la Timone

🇫🇷

Marseille, France

© Copyright 2025. All Rights Reserved by MedPath